Advances in drug design, such as dual and triple agonists (e.g., GLP-1/gastric inhibitory peptide (GIP) and GLP-1/GIP/glucagon receptor agonists), are expanding the therapeutic impact of these ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...

Insulin, which regulates blood glucose (sugar), is an example of a peptide hormone. Your body naturally produces the hormones GLP-1 and gastric inhibitory polypeptide receptor (GIP), known as ...

Mounjaro (Terzepatide) is a dual GLP-1/GIP (Gastric Inhibitory Peptide) receptor agonist, which may offer better blood sugar control and enhanced weight loss compared to traditional GLP-1 agonists.

The first planned combination will pair petrelintide with Roche’s glucagon-like peptide 1/gastric inhibitory polypeptide (GLP-1/GIP) agonist candidate CT-388. Inherited by Roche through its $2 ...

Palatin (PTN) announced positive appetite suppression results from its BMT-801 Phase 2 obesity study. The study included a co-administered ...

OBJECTIVE Gastric bypass (GB ... Plasma levels of the incretin glucagon-like peptide 1 (GLP-1) are dramatically increased after GB, suggesting that its action contributes to alteration in ...

Data from Phase 2 Trial VGX-001-012 of Mizagliflozin in Post Bariatric Hypoglycemia will be Presented RALEIGH, NC / ACCESS Newswire / April 15, 2025 /Vogenx, Inc., a clinical-stage developer of novel ...